Related Experiment Video
Updated: Jun 4, 2026
Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
Published on: April 3, 2026
Management of recurrent gastrointestinal stromal tumors
Joshua H Winer1, Chandrajit P Raut
1Department of Surgery, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.
Abstract:
Recurrence after resection of primary gastrointestinal stromal tumor (GIST) is an unfortunately all-too-common phenomenon. The principal treatment for recurrent GIST is the first-line tyrosine kinase inhibitor (TKI) imatinib mesylate. Those who progress on, or are intolerant of imatinib, are treated with second-line TKI sunitinib malate. Cytoreductive surgery may be considered as an "adjuvant" therapy for patients with disease stabilized on imatinib, and, on an individual basis, sunitinib.
Insights
Recurrence of gastrointestinal stromal tumors (GIST) is common. Treatment involves tyrosine kinase inhibitors (TKIs) like imatinib and sunitinib, with surgery considered in select cases.
Area of Science:
- Oncology
- Gastrointestinal Surgery
- Medical Oncology
Background:
- Recurrence of primary gastrointestinal stromal tumors (GIST) following surgical resection is a significant clinical challenge.
- Effective management strategies are crucial for improving patient outcomes after GIST treatment.
Purpose of the Study:
- To outline the current treatment paradigms for recurrent GIST.
- To discuss the role of tyrosine kinase inhibitors (TKIs) and cytoreductive surgery in managing advanced GIST.
Main Methods:
- Review of established treatment protocols for recurrent GIST.
- Discussion of therapeutic options including imatinib mesylate and sunitinib malate.
- Consideration of adjuvant surgical approaches for stabilized disease.
Main Results:
- Imatinib mesylate is the primary therapy for recurrent GIST.
- Sunitinib malate serves as a second-line treatment for patients progressing on or intolerant to imatinib.
- Cytoreductive surgery may be utilized as an adjuvant therapy in specific clinical scenarios.
Conclusions:
- The management of recurrent GIST relies on a stepwise approach utilizing TKIs.
- Surgical intervention can be a valuable adjunct to systemic therapy in select patients with stabilized recurrent GIST.
Related Concept Videos
01:21Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD:
01:25Peptic Ulcer Disease V: Surgical Management and Nursing Care
Surgical Interventions for Peptic Ulcer Disease
01:26Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
01:29Gastroesophageal Reflux Disease II: Clinical Features and Management
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...